AbCellera Biologics
ABCL
114 hedge funds and large institutions have $1.99B invested in AbCellera Biologics in 2021 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 50 increasing their positions, 8 reducing their positions, and 20 closing their positions.
525% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 8
140% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 20
51% more call options, than puts
Call options by funds: $33.8M | Put options by funds: $22.5M
33% more funds holding
Funds holding: 86 → 114 (+28)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
6.61% more ownership
Funds ownership: 26.81% → 33.42% (+6.6%)
18% less capital invested
Capital invested by funds: $2.42B → $1.99B (-$431M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Allianz Asset Management
Munich,
Germany
|
+$274M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$255M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$141M |
| 4 |
GCAC
Guardian Capital Advisors (Canada)
Toronto,
Ontario, Canada
|
+$110M |
| 5 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
+$55.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$648M |
| 2 |
O
OrbiMed
New York
|
-$54.5M |
| 3 |
AWG
Alpha Wave Global
New York
|
-$30M |
| 4 |
DFO
Duquesne Family Office
New York
|
-$22.4M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$17.8M |
ABCL Hedge Fund Activity: Q2 2021 in Review
114 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in AbCellera Biologics (ABCL) for Q2 2021, worth a combined $1.99B — down 18% from $2.42B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ABCL positions and 20 closed out — a net gain of 28 holders — while 50 added to existing stakes and 8 trimmed.
The largest buyer was Allianz Asset Management, opening a new position worth an estimated $274M. The largest seller was Viking Global Investors, exiting entirely with an estimated $648M sold.
- 114 institutional investors held AbCellera Biologics (ABCL) as of Q2 2021, up from 86 in Q1 2021.
- Funds reported $1.99B of AbCellera Biologics stock for Q2 2021, down 18% quarter-over-quarter.
- 48 funds opened new AbCellera Biologics positions in Q2 2021 and 20 closed out, a net change of +28 holders.
- The largest AbCellera Biologics buyer in Q2 2021 was Allianz Asset Management, an estimated $274M added.
- The largest AbCellera Biologics seller in Q2 2021 was Viking Global Investors, an estimated $648M sold.
Based on aggregated 13F filings for Q2 2021.